222 related articles for article (PubMed ID: 17875784)
1. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.
Al-Ejeh F; Darby JM; Pensa K; Diener KR; Hayball JD; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5519s-5527s. PubMed ID: 17875784
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G
Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799
[TBL] [Abstract][Full Text] [Related]
3. Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance.
Al-Ejeh F; Staudacher AH; Smyth DR; Darby JM; Denoyer D; Tsopelas C; Hicks RJ; Brown MP
J Nucl Med; 2014 May; 55(5):772-9. PubMed ID: 24676755
[TBL] [Abstract][Full Text] [Related]
4. The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs.
Al-Ejeh F; Darby JM; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5509s-5518s. PubMed ID: 17875783
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.
Al-Ejeh F; Darby JM; Brown MP
PLoS One; 2009; 4(2):e4630. PubMed ID: 19247485
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4.
Schmidberger H; Buchsbaum DJ; Blazar BR; Everson P; Vallera DA
Cancer Res; 1991 Apr; 51(7):1883-90. PubMed ID: 2004371
[TBL] [Abstract][Full Text] [Related]
7. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
Pedley RB; Hill SA; Boxer GM; Flynn AA; Boden R; Watson R; Dearling J; Chaplin DJ; Begent RH
Cancer Res; 2001 Jun; 61(12):4716-22. PubMed ID: 11406542
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
9. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
[TBL] [Abstract][Full Text] [Related]
10. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia.
Uno S; Kinoshita Y; Azuma Y; Tsunenari T; Yoshimura Y; Iida S; Kikuchi Y; Yamada-Okabe H; Fukushima N
Oncol Rep; 2007 May; 17(5):1189-94. PubMed ID: 17390064
[TBL] [Abstract][Full Text] [Related]
12. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice.
Iakoubov LZ; Torchilin VP
Oncol Res; 1997; 9(8):439-46. PubMed ID: 9436197
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
14. APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.
Al-Ejeh F; Darby JM; Tsopelas C; Smyth D; Manavis J; Brown MP
PLoS One; 2009; 4(2):e4558. PubMed ID: 19247492
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between sensitivity of tumor cells to chemotherapeutic agent in vivo and in vitro: experiment with mouse lymphoma cells].
Li CG; Li ML; Shu XH; Jia YJ; Liu YJ; Li M
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(22):1576-8. PubMed ID: 17785116
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
17. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
[TBL] [Abstract][Full Text] [Related]
18. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma.
Burton J; Mishina D; Cardillo T; Lew K; Rubin A; Goldenberg DM; Gold DV
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3065s-3072s. PubMed ID: 10541345
[TBL] [Abstract][Full Text] [Related]
19. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
[TBL] [Abstract][Full Text] [Related]
20. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
